Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Oct 25, 2011, 08:11 ET from Reportlinker

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0336526/Fibromyalgia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global FM market. The report identifies the key trends shaping and driving the global FM market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global FM sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The global market for Fibromyalgia (FM) was valued at $1.7 billion in 2010 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.4 billion by 2018. The restricted growth in the market is due to the unavailability of approved drugs in the EU and Japan market, expected patent expiry of Cymbalta (2013) and Lyrica (2018) and lack of newer therapies in late stage FM therapeutics pipeline. Currently, FDA (Food and Drug Administration) has approved three drugs for the treatment of FM. Lyrica (pregabalin) was the first drug approved in June 2007 followed by Cymbalta (duloxetine) in June 2008 and Savella (milnacipran) in January 2009. Marketing authorization of these drugs has been rejected by EMEA (European Medical Agency) due low effectiveness and high adverse reactions associated with the drugs. Cymbalta was the first drug to be rejected by EMEA in 2008, followed by Lyrica in 2009 and Savella in 2010. However, increasing prevalence and diagnosis is expected to drive the future FM therapeutics market.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the FM market. Its scope includes -

- Annualized global FM market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as therapies based on SSRI and GABA agonist calcium channel blocker, sodium channel blocker, nonrepinephrine reuptake inhibitor, NMDA antagonist.

- Analysis of the current and future competition in the global FM market. Key market players covered are the Pfizer, Jazz Pharmaceuticals and UCB.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the FM therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global FM market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global FM market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global FM market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Fibromyalgia Therapeutics: Executive Summary 9

2.1 The Fibromyalgia (FM) Therapeutics Market is Forecast to Show Slow Growth Until 2018 9

2.2 Weak Market Served by Three FDA Approved Products Targeting Symptomatic Relief 10

2.3 Fibromyalgia Therapeutics Market has High Unmet Need 10

2.4 Weak Pipeline with Lack of Promising Molecules 11

2.5 Implications for the Future Market 12

3 Fibromyalgia Therapeutics: Introduction 13

3.1 Overview 13

3.2 Epidemiology 13

3.2.1 Prevalence 13

3.2.2 Co-Morbidities 15

3.2.3 Quality of Life: 15

3.2.4 Economic Burden: 16

3.3 Etiology and Pathophysiology 16

3.4 Symptoms 17

3.5 Diagnosis 18

3.6 Treatment and Management Pattern 20

3.7 Referral Pathway 22

3.8 GlobalData Pipeline Report Guidance 22

4 Fibromyalgia Therapeutics: Market Characterization 24

4.1 Fibromyalgia Therapeutics Market Size (2005 - 2010) - Global 24

4.2 Fibromyalgia Therapeutics Market Forecast (2010 - 2018) - Global 25

4.3 Fibromyalgia Therapeutics Market Size (2005 - 2010): The US 26

4.4 Fibromyalgia Therapeutics Market Forecast (2010-2018): The US 27

4.5 Fibromyalgia Therapeutics Market (2005 - 2010): France 28

4.6 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): France 29

4.7 Fibromyalgia Therapeutics Market (2005 - 2010): Germany 30

4.8 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Germany 32

4.9 Fibromyalgia Therapeutics Market (2005 - 2010): Italy 33

4.10 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Italy 34

4.11 Fibromyalgia Therapeutics Market (2005 - 2010): Spain 35

4.12 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Spain 36

4.13 Fibromyalgia Therapeutics Market (2005 - 2010): The UK 37

4.14 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): The UK 38

4.15 Fibromyalgia Therapeutics Market (2005 - 2010): Japan 39

4.16 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Japan 40

4.17 Drivers and Barriers for the Fibromyalgia Therapeutics Market 41

4.17.1 Drivers for the Fibromyalgia Therapeutics Market 41

4.17.2 Barriers for the Fibromyalgia Therapeutics Market 41

4.18 Opportunity and Unmet Need Analysis 42

4.19 Key Takeaway 43

5 Fibromyalgia Therapeutics: Competitive Assessment 44

5.1 Overview 44

5.2 Strategic Competitor Assessment 44

5.3 Product Profile for the Major Marketed Products in the Fibromyalgia Therapeutics Market 46

5.3.1 Lyrica (pregabalin) 46

5.3.2 Cymbalta (duloxetine) 48

5.3.3 Savella (milnacipran) 50

6 Fibromyalgia Therapeutics: Pipeline Assessment 52

6.1 Overview 52

6.2 Strategic Pipeline Assessment 52

6.3 Fibromyalgia Therapeutics Pipeline – Pipeline by Phases of Development 52

6.3.1 Fibromyalgia Therapeutics – Filed Pipeline 53

6.3.2 Fibromyalgia Therapeutics – Phase III Pipeline 53

6.3.3 Fibromyalgia Therapeutics – Phase II Pipeline 53

6.3.4 Fibromyalgia Therapeutics – Phase I Pipeline 54

6.4 Fibromyalgia Therapeutics Market – Pipeline by Mechanism of Action 54

6.5 Technology Trends Analytical Framework 55

6.6 Molecule Profile for Drugs under Late Stage Development 57

6.6.1 Lyrica (Pregabalin) 57

6.6.2 JZP-6 (sodium oxybate) 58

7 Fibromyalgia Therapeutics: Clinical Trials Mapping 61

7.1 Clinical Trials by Country (US, EU5 & Japan) 61

7.2 Clinical Trials by Phase 62

7.3 Clinical Trials by Trial Status 63

7.4 Prominent Sponsors 64

7.5 Key Companies Participating in Therapeutics Clinical Trials 65

8 Fibromyalgia Therapeutics: Stategic Assessment 67

8.1 Key Events Impacting on the Future Market 67

8.2 Fibromyalgia Therapeutics: Implications for Future Market Competition 67

9 Fibromyalgia Therapeutics: Future Players 70

9.1 Introduction 70

9.2 Company Profiles 71

9.2.1 Jazz Pharmaceuticals Inc. 71

9.2.2 Pfizer 72

9.2.3 UCB SA 73

9.2.4 Other Companies in the Fibromyalgia Therapeutics Market 74

10 Fibromyalgia Therapeutics: Licensing and Partnership Deals 76

11 Fibromyalgia Therapeutics: Appendix 78

11.1 Market Definitions 78

11.2 Abbreviations 78

11.3 Methodology 79

11.3.1 Coverage 79

11.3.2 Secondary Research 79

11.3.3 Forecasting 80

11.3.4 Primary Research 81

11.3.5 Expert Panel Validation 82

11.4 Contact Us 82

11.5 Disclaimer 82

11.6 Bibliography 83

List of Tables

Table 2: Fibromyalgia Therapeutics: Prevalence of FM in Top Seven Countries 15

Table 3: Fibromyalgia Therapeutics: Prevalence (%) of Co-Morbid Conditions Associated with FM 16

Table 4: Fibromyalgia Therapeutics: Quality of Life 17

Table 5: Fibromyalgia Therapeutics: NIH Spending 17

Table 6: Fibromyalgia Therapeutics: Prescribed Drugs 22

Table 8: Fibromyalgia Therapeutics Market, Global, Revenue($m), 2005-2010 26

Table 10: Fibromyalgia Therapeutics Market, Global, Forecast($m), 2010-2018 27

Table 12: Fibromyalgia Therapeutics Market, The US, Revenue($m), 2005-2010 28

Table 14: Fibromyalgia Therapeutics Market, The US, Forecast($m), 2010-2018 29

Table 16: Fibromyalgia Therapeutics Market, France, Revenue($m), 2005-2010 30

Table 18: Fibromyalgia Therapeutics Market, France, Forecast($m), 2010-2018 31

Table 20: Fibromyalgia Therapeutics Market, Germany, Revenue($m), 2005-2010 32

Table 22: Fibromyalgia Therapeutics Market, Germany, Forecast ($m), 2010-2018 33

Table 24: Fibromyalgia Therapeutics Market, Italy, Revenue ($m), 2005-2010 34

Table 26: Fibromyalgia Therapeutics Market, Italy, Forecast ($m), 2010-2018 35

Table 28: Fibromyalgia Therapeutics Market, Spain, Revenue ($m), 2005-2010 36

Table 30: Fibromyalgia Therapeutics Market, Spain, Forecast ($m), 2010-2018 37

Table 32: Fibromyalgia Therapeutics Market, UK, Revenue ($m), 2005-2010 38

Table 34: Fibromyalgia Therapeutics Market, UK, Forecast ($m), 2010-2018 39

Table 36: Fibromyalgia Therapeutics Market, Japan, Revenue ($m), 2005-2010 40

Table 38: Fibromyalgia Therapeutics Market, Japan, Forecast ($m), 2010-2018 41

Table 39: Fibromyalgia Therapeutics: Unmet Need Gap 43

Figure 41: Strategic Competitor Assessment of the Major Marketed Products for Fibromyalgia, 2011 46

Table 43: Fibromyalgia Therapeutics – Filed Clinical Pipeline, 2011 54

Table 44: Fibromyalgia Therapeutics – Phase III Clinical Pipeline, 2011 54

Table 45: Fibromyalgia Therapeutics – Phase II Clinical Pipeline, 2011 54

Table 46: Fibromyalgia Therapeutics – Phase l Pipeline, 2011 55

Table 50: Fibromyalgia Therapeutics – Most Promising Drugs Under Development, 2011 58

Table 53: Fibromyalgia Therapeutics, Clinical Trials by Country,2011 63

Table 55: Fibromyalgia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 64

Table 57: Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2011 65

Table 26: Fibromyalgia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 65

Table 27: Fibromyalgia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 66

Table 61: Fibromyalgia Therapeutics, Global, Clinical Trials by Top Companies, 2011 67

Table 29: Jazz Pharmaceuticals - CNS Pipeline Portfolio, 2011 72

Table 65: Pfizer Inc. - CNS Pipeline Portfolio, 2011 73

Table 66: Actelion Pharmaceuticals Ltd - CNS Pipeline Portfolio, 2011 74

Table 68: Other Companies in the Pipeline, 2011 75

Table 69: Licensing and Partnership Deals, 2006-2011 77

List of Figures

Figure 1: Fibromyalgia Therapeutics Market, Global, Revenues ($bn), 2005-2018 10

Figure 2: Opportunity and Unmet Need in the Fibromyalgia Therapeutics Market, 2010 12

Figure 1: Fibromyalgia Therapeutics: Prevalence With Age 14

Figure 3: Fibromyalgia Therapeutics: 18 Tender Points 20

Figure 4: Fibromyalgia Therapeutics: Referral Pathway 23

Figure 7: Fibromyalgia Therapeutics Market, Global, Revenue($m), 2005-2010 25

Figure 9: Fibromyalgia Therapeutics Market, Global, Forecast ($m), 2010-2018 26

Figure 11: Fibromyalgia Therapeutics Market, The US, Revenue($m), 2005-2010 28

Figure 13: Fibromyalgia Therapeutics Market, The US, Forecast($m), 2010-2018 29

Figure 15: Fibromyalgia Therapeutics Market, France, Revenue($m), 2005-2010 29

Figure 17: Fibromyalgia Therapeutics Market, France, Forecast($m), 2010-2018 31

Figure 19: Fibromyalgia Therapeutics Market, Germany, Revenue($m), 2005-2010 32

Figure 21: Fibromyalgia Therapeutics Market, Germany, Forecast ($m), 2010-2018 33

Figure 23: Fibromyalgia Therapeutics Market, Italy, Revenue ($m), 2005-2010 34

Figure 25: Fibromyalgia Therapeutics Market, Italy, Forecast ($m), 2010-2018 35

Figure 27: Fibromyalgia Therapeutics Market, Spain, Revenue ($m), 2005-2010 36

Figure 29: Fibromyalgia Therapeutics Market, Spain, Forecast ($m), 2010-2018 37

Figure 31: Fibromyalgia Therapeutics Market, UK, Revenue ($m), 2005-2010 38

Figure 33: Fibromyalgia Therapeutics Market, UK, Forecast ($m), 2010-2018 39

Figure 35: Fibromyalgia Therapeutics Market, Japan, Revenue ($m), 2005-2010 40

Figure 37: Fibromyalgia Therapeutics Market, Japan, Forecast ($m), 2010-2018 41

Figure 40: Opportunity and Unmet Need in the Fibromyalgia Therapeutics Market, 2010 43

Figure 4: Pain Reduction of Approved Products (Lyrica, Cymbalta and Savella) 47

Figure 5: Fibromyalgia Therapeutics: Molecular Structure of Lyrica 48

Figure 6: Fibromyalgia Therapeutics: Molecular Structure of Cymbalta 50

Figure 42: Fibromyalgia Therapeutics, Pipeline by Phase of Development, 2011 53

Figure 47: Fibromyalgia Therapeutics Market – Pipeline by Mechanism of Action, 2011 55

Figure 48: Technology Trends Analytic Framework of the Fibromyalgia Therapeutics Pipeline, 2011 56

Figure 49: Technology Trends Analytic Framework of the Fibromyalgia Therapeutics Pipeline - Description, 2011 57

Figure 51: Fibromyalgia Therapeutics, Molecular Structure of Lyrica 59

Figure 52: Fibromyalgia Therapeutics - Clinical Trials by Country, 2011 62

Figure 54: Fibromyalgia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 63

Figure 56: Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2011 64

Figure 58: Fibromyalgia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 65

Figure 59: Fibromyalgia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 66

Figure 60: Fibromyalgia Therapeutics, Global, Clinical Trials by Top Companies, 2011 67

Figure 62: Fibromyalgia Therapeutics Market, Drivers and Barriers, 2011 68

Figure 63: Implications for Future Market Competition in the Fibromyalgia Therapeutics Market, 2011 68

Figure 64: Fibromyalgia Therapeutics – Clinical Pipeline by Company, 2011 70Jazz Pharmaceuticals Inc.

Pfizer

UCB SA

To order this report:

Drug and Medication Industry: Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Drug and Medication Business News

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com